Agendia Raises $65 Million in a Private Round of Equity Financing

Agendia Raises $65 Million in a Private Round of Equity Financing PR Newswire IRVINE, California and AMSTERDAM, May 31, 2012 IRVINE, California and AMSTERDAM, May 31, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that the company has raised USD $65 million in a private round of equity financing. "The support we have received in this round of financing is a strong reflection of our recent growth and confidence in the commercialization of our product pipeline in the future," said David Macdonald, CEO of Agendia. "We will use these funds to expand commercialization of our current breast cancer Symphony suite of tests, as well as for development of our personalized medicine pipeline. We have recently launched our Symphony suite in an FFPE format, and we are preparing to launch our ColoPrint recurrence test for stage II colon cancer prognosis and prediction." The financing round was led by the Debiopharm Group™ (Debiopharm), a leading drug development company based in Switzerland, with significant support from all of Agendia's current investors, including; The Van Herk Group, ING Corporate Investments, Breedinvest and Gilde Healthcare. Agendia also brought in other new investors for the financing round, including Korys, the investment structure of the Colruyt family and others.